High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions

References

• Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23–15.
   PubMed Web of Science ®Google Scholar
• Lund IK, Illemann M, Thurison T, Christensen IB, Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011;12:1744–60.
   PubMed Web of Science ®Google Scholar
• Mazar AP, Ahn RW, O’halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011;17:1970–78.
   PubMed Web of Science ®Google Scholar
• Stroomberg HV, Kristensen G, Drimer Berg K, Lippert S, Brasso K, Røder MA. The association between plasma levels of intact and cleaved uPAR levels and the risk of biochemical recurrence after radical prostatectomy for prostate cancer. Diagnostics. 2020;10:877.
   Web of Science ®Google Scholar
• Liu KL, Fan JH, Wu J. Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis. Clin Lab. 2017;63:871–80.
   PubMed Web of Science ®Google Scholar
• de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13–39.
   PubMed Web of Science ®Google Scholar
• Yuan C, Guo Z, Yu S, Jiang L, Huang M. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today. 2021;26:1076–85.
   PubMed Web of Science ®Google Scholar
• Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JGM, Foekens JA. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 2004;64:4563–68.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90.
   PubMed Web of Science ®Google Scholar
• Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res. 2001;7(8):2448–57.
   PubMed Web of Science ®Google Scholar
• Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009;284:22825–33.
   PubMed Web of Science ®Google Scholar
• Chandran VI, Eppenberger-Castori S, Venkatesh T, Vine KL, Ranson M. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience. 2015;2:207–24.
   PubMedGoogle Scholar
• Uhr J. uPAR and HER2 genes are usually co-amplified in individual breast cancer cells from blood and tissues. Breast Care. 2008;3:16–19.
   PubMed Web of Science ®Google Scholar
• Li C, Cao S, Liu Z, Ye X, Chen L, Meng S. Rnai-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. Int J Cancer. 2010;127:1507–16.
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11:263–75.
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479–91.
   PubMed Web of Science ®Google Scholar
• LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013;73:2070–81.
   PubMed Web of Science ®Google Scholar
• Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. J Mol Biol. 2015;427:1389–403.
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010;12:778–88.
   PubMed Web of Science ®Google Scholar
• Rullo AF, Fitzgerald KJ, Muthusamy V, Liu M, Yuan C, Huang M, Kim M, Cho AE, Spiegel DA. Re-engineering the immune response to metastatic cancer: antibody-recruiting small molecules targeting the urokinase receptor. Angew Chem. 2016;128:3706–10.
   Google Scholar
• Mani T, Wang F, Knabe WE, Sinn AL, Khanna M, Jo I, Sandusky GE, Sledge GW, Jones DR, Khanna R, et al. Small-molecule inhibition of the uPar·upa interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem. 2013;21(7):2145–55.
   PubMed Web of Science ®Google Scholar
• Minopoli M, Polo A, Ragone C, Ingangi V, Ciliberto G, Pessi A, Sarno S, Budillon A, Costantini S, Carriero MV. Structure-function relationship of an urokinase receptor-derived peptide which inhibits the formyl peptide receptor type 1 activity. Sci Rep. 2019;9:12169.
   PubMed Web of Science ®Google Scholar
• Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011;17:459–71.
   PubMed Web of Science ®Google Scholar
• Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van’t Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, et al. Antibody-drug conjugates targeting the urokinase receptor (uPAR) as a possible treatment of aggressive breast cancer. Antibodies. 2019;8(4):54.
   Web of Science ®Google Scholar
• Kriegbaum MC, Persson M, Haldager L, Alpízar-Alpízar W, Jacobsen B, Gårdsvoll H, Kjær A, Ploug M. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets. 2011;12:1711–28.
   PubMed Web of Science ®Google Scholar
• Baart VM, Houvast RD, de Geus-Oei LF, Quax PHA, Kuppen PJK, Vahrmeijer AL, Sier CFM. Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer. EJNMMI Res. 2020;10:87.
   PubMed Web of Science ®Google Scholar
• Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem. 2010;285:26878–88.
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Uno Y, Utoh M, Yamazaki H. Importance of cynomolgus monkeys in development of monoclonal antibody drugs. Drug Metab Pharmacokinet. 2019;34:55–63.
   PubMed Web of Science ®Google Scholar
• Winters A, McFadden K, Bergen J, Landas J, Berry KA, Gonzalez A, Salimi-Moosavi H, Murawsky CM, Tagari P, King CT. Rapid single B cell antibody discovery using nanopens and structured light. mAbs. 2019;11:1025–35.
   PubMed Web of Science ®Google Scholar
• Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42:1143–58.
   PubMed Web of Science ®Google Scholar
• Yeku O, Frohman MA. Rapid amplification of cDNA ends (RACE). Methods Mol Biol. 2011;703:107–22.
   PubMedGoogle Scholar
• Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259–67.
   PubMed Web of Science ®Google Scholar
• Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp Mol Med. 2019;51:1–9.
   Web of Science ®Google Scholar
• Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 2013;11:307.
   PubMed Web of Science ®Google Scholar
• Forsström B, Bisławska Axnäs B, Rockberg J, Danielsson H, Bohlin A, Uhlen M, Mantis NJ. Dissecting antibodies with regards to linear and conformational epitopes. PLoS ONE. 2015;10:e0121673.
   PubMed Web of Science ®Google Scholar
• McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–43.
   PubMed Web of Science ®Google Scholar
• Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, Vici P. Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med. 2019;8:254.
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148–57.
   PubMed Web of Science ®Google Scholar
• Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: promises and challenges. mAbs. 2021;13:1951427.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn M-F, Dugan EJ, Steri V, Hann B, Shokat KM, Craik CS. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022;40:1060–9.e7.
   PubMed Web of Science ®Google Scholar
• Ferraris GMS, Schulte C, Buttiglione V, De Lorenzi V, Piontini A, Galluzzi M, Podestà A, Madsen CD, Sidenius N. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins. Embo J. 2014;33:2458–72.
   PubMed Web of Science ®Google Scholar
• LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014;4:267–79.
   PubMed Web of Science ®Google Scholar
• Gårdsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem. 2007;282:13561–72.
   PubMed Web of Science ®Google Scholar
• Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24.
   PubMed Web of Science ®Google Scholar
• Mahmood N, Arakelian A, Khan HA, Tanvir I, Mazar AP, Rabbani SA. uPAR antibody (huATN-658) and zometa reduce breast cancer growth and skeletal lesions. Bone Res. 2020;8:1–12.
   PubMed Web of Science ®Google Scholar
• Han C, Gunn GR, Marini JC, Shankar G, Han Hsu H, Davis HM. Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys. Drug Metab Dispos. 2015;43:762–70.
   PubMed Web of Science ®Google Scholar
• Derebe MG, Nanjunda RK, Gilliland GL, Lacy ER, Chiu ML. Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors. Immunol Lett. 2018;197:1–8.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020;26(9):1422–27.
   PubMed Web of Science ®Google Scholar
• Dixon KJ, Wu J, Walcheck B. Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells. Cancers. 2021;13:312.
   PubMed Web of Science ®Google Scholar
• St-Pierre F, Bhatia S, Chandra S. Harnessing natural killer cells in cancer immunotherapy: a review of mechanisms and novel therapies. Cancers. 2021;13:1988.
   PubMed Web of Science ®Google Scholar
• Yogo R, Yamaguchi Y, Watanabe H, Yagi H, Satoh T, Nakanishi M, Onitsuka M, Omasa T, Shimada M, Maruno T, et al. The fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III. Sci Rep. 2019;9(1):11957.
   PubMedGoogle Scholar
• Wang W, Chen Q. Antigen improves binding of IgGs to FcγRs in SPR analysis. Anal Biochem. 2022;640:114411.
   PubMed Web of Science ®Google Scholar
• Sun Y, Izadi S, Callahan M, Deperalta G, Wecksler AT. Antibody–receptor interactions mediate antibody-dependent cellular cytotoxicity. J Biol Chem. 2021;297:100826.
   PubMed Web of Science ®Google Scholar
• Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, et al. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol. 2014;88(21):12895–906.
   PubMed Web of Science ®Google Scholar
• Tolbert WD, Sherburn RT, Van V, Pazgier M. Structural basis for epitopes in the gp120 cluster a region that invokes potent effector cell activity. Viruses. 2019;11:69.
   PubMed Web of Science ®Google Scholar
• Mielke D, Bandawe G, Pollara J, Abrahams MR, Nyanhete T, Moore PL, Thebus R, Yates NL, Kappes JC, Ochsenbauer C, et al. Antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies constrain neutralizing antibody escape pathway. Front Immunol. 2019;10:2875.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4:511–27.
   PubMed Web of Science ®Google Scholar
• Pirazzoli V, Ferraris GMS, Sidenius N. Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth. Blood. 2013;121:2316–23.
   PubMed Web of Science ®Google Scholar
• Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380–88.
   PubMed Web of Science ®Google Scholar
• Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996;134:1563–71.
   PubMed Web of Science ®Google Scholar
• Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol. 2001;189:23–33.
   PubMed Web of Science ®Google Scholar
• Madsen CD, Ferraris GMS, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007;177:927–39.
   PubMed Web of Science ®Google Scholar
• Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021;23:84.
   PubMed Web of Science ®Google Scholar
• Vilhardt F, Nielsen M, Sandvig K, van Deurs B, Pfeffer SR. Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized madin–darby canine kidney epithelial cells. Mol Biol Cell. 1999;10:179–95.
   PubMed Web of Science ®Google Scholar
• Cortese K, Sahores M, Madsen CD, Tacchetti C, Blasi F, Blagosklonny MV. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS ONE. 2008;3:e3730.
   PubMed Web of Science ®Google Scholar
• Noh H, Hong S, Huang S. Role of urokinase receptor in tumor progression and development. Theranostics. 2013;3:487–95.
   PubMed Web of Science ®Google Scholar
• Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem. 1987;262:4437–40.
   PubMed Web of Science ®Google Scholar
• Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem. 1989;264:1180–89.
   PubMed Web of Science ®Google Scholar
• Huai Q, Zhou A, Lin L, Mazar A P, Parry G C, Callahan J, Shaw D E, Furie B, Furie B C and Huang M. (2008). Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol, 15(4), 422–423. 10.1038/nsmb.1404
   PubMed Web of Science ®Google Scholar
• Wilmore JR, Jones DD, Allman D. Improved resolution of plasma cell subpopulations by flow cytometry. Eur J Immunol. 2017;47:1386–88.
   PubMed Web of Science ®Google Scholar
• Madeira F, Pearce M, Tivey ARN, Basutkar P, Lee J, Edbali O, Madhusoodanan N, Kolesnikov A, Lopez R. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 2022;50:W276–279.
   PubMed Web of Science ®Google Scholar
• Kumar S, Stecher G, Li M, Knyaz C, Tamura K, Mega X, Battistuzzi FU. Molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–49.
   PubMed Web of Science ®Google Scholar